CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on Seladelpar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
July 23, 2020 10:35 AM EDTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the clinical hold on seladelpar was lifted. The analyst thinks this is just the beginning of a major recovery for shares.
Merle commented, "This morning CBAY announced the FDA lifted the clinical hold on seladelpar across all indications (PBC, PSC, NASH). This is a... More
